1. Chiral cysteine-copper ion-based assemblies for improved phototherapy.
- Author
-
Sun X, Ye Q, Liang Y, Yuan Y, Zhu L, Zhang Q, Han J, and Guo R
- Subjects
- Humans, Copper pharmacology, Cysteine, HeLa Cells, Phototherapy methods, Indocyanine Green chemistry, Cell Line, Tumor, Photochemotherapy, Nanoparticles chemistry
- Abstract
Phototherapy, encompassing photothermal therapy and photodynamic therapy, is gaining attention as an appealing cancer treatment modality. To enhance its clinical implementation, a comprehensive exploration of the pivotal factors influencing phototherapy is warranted. In this study, the L/d-cysteine (Cys)-copper ion (Cu
2+ ) chiral nanoparticles, through the assembly of L/d-Cys-Cu2+ coordination complexes, were constructed. We found that these nanoparticles interacted with chiral liposomes in a chirality-dependent manner, with d-Cys-Cu2+ nanoparticles exhibiting more than three times stronger binding affinity than l-Cys-Cu2+ nanoparticles. Furthermore, we demonstrated that the d-Cys-Cu2+ nanoparticles were more efficiently internalized by Hela cells in contrast with l-Cys-Cu2+ . On this basis, indocyanine green (ICG), acting as both photothermal and photodynamic agent, was encapsulated into L/d-Cys-Cu2+ nanoparticles. Experimental results showed that the l-Cys-Cu2+ -ICG and d-Cys-Cu2+ -ICG nanoparticles displayed almost identical photothermal performance and singlet oxygen (1 O2 ) generation capability in aqueous solution. However, upon laser irradiation, the d-Cys-Cu2+ -ICG nanoparticles achieved enhanced anti-tumor effects compared to l-Cys-Cu2+ -ICG due to their chirality-promoted higher cellular uptake efficiency. These findings highlight the crucial role of chirality in phototherapy and provide new perspectives for engineering cancer therapeutic agents., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF